Assessment for Enrollment Rate of Multidrug-Resistant Tuberculosis (MDR-TB) Cases in 2017 in Kano State, North West Nigeria

Download Article

DOI: 10.21522/TIJPH.2013.07.04.Art016

Authors : Musa K. Bawa, Mustapha Mukhtar, Ado Umar


Background: Multi-drug resistant tuberculosis (MDR-TB) is one of the greatest challenges to controlling tuberculosis worldwide, Nigeria inclusive. We conducted a descriptive, cross-sectional study to identify and access the enrollment rate of MDR-TB cases in 2017 in Kano state, north west Nigeria

Methods: We reviewed the MDR-TB patients line list of Kano state tuberculosis and leprosy control program (TBLCP) using the National TBLCP line listing template. The data was analyzed using Epi Info version 3.5.4 and Microsoft Excel 2007.

Results: A total of 121 MDR TB cases were managed in the year 2017 in Kano state, of which 115 (95.0%) were identified within the year, 5 (4,1%) were referred in from other states, 1 (0.9%) carried over to the year. Of the 121 cases managed, 82 (67.8%) were males. Of the 121 cases managed in the year 2017, 77 (63.6%) were enrolled, 3 (2.5%) died before enrolment, 5 (4.1%) refused treatment and 14 (11.6%) loss to follow up. The highest number of MDR cases managed, 38 (31.4%) was in Q3 while Q1 had the lowest number of cases managed as 20 (16.5%). Q3 had the highest enrollment rate of 89.5% (34/38) while Q4 had the lowest enrollment rate of 17.9% (5/28).

Conclusions: The MDR TB enrollment rate in Kano state in 2017 is low. Majority of the cases were enrolled in Q3 of the year. There is high rate of loss to follow up. There is need for Kano TBLCP to institute prompt identification of cases for immediate enrollment.

Keywords: Assessment, enrollment rate, Multidrug-resistant tuberculosis, Kano state, north west Nigeria.


[1].   World Health Organization: WHO report 2013.Global Tuberculosis control. Geneva: World Health Organization; 2013. ( WHO. 2013.

[2].   World Health Organization: WHO report 2011. Global Tuberculosis Control: Surveillance, planning, Financing. WHO/HTM/TB/2010. Geneva, Switzerland: WHO; 2010.

[3].   World Health Organisation. Multidrug and extensively drug-resistant TB. Indian J Tuberc. 2010;57(4):180–91. Available from:

[4].   Federal Ministry of Health of Ethiopia: Guideline for program and clinical management of drug resistant tuberculosis. 5th edition. Addis Ababa, Ethiopia: FMOH; 2009.

[5].   WHO: Anti-tuberculosis drug resistance in the world. Third global report. The WHO/IUATLD Global Project on Ant tuberculosis Drug Resistance Surveillance, 1999–2002. Geneva: World Health Organization; 2004.

[6].   Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9: e1001300.

[7].   Fawcet t IW, Watkins BJ. Initial resistance of Mycobacterium tuberculosis in Northern Nigeria Tubercle 1976; 57:71-3.

[8].   World Health Organization (WHO). Multidrug and extensively drug resistant TB (M/XDR-TB): 2012 global report on surveillance and response (WHO/HTM/TB/2010.3). Geneva: WHO, 2012.

[9].   World Health Organization. Global Tuberculosis Control: WHO report 2016. Geneva, Switzerland: World Health Organization, 2016.

[10].  The World Gazetteer. Profile of Kano, the capital city of State. Archived from the original on 9 February2013. Retrieved 2007-03-27. Accessed on 07/10/2019 from URL: http://www.http/kano/profile.

[11].  World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. WHO/HTM/TB/2011.1Geneva: WHO, 2011.

[12].  World Health Organization. Global tuberculosis report 2015. WHO/HTM/TB/2015.54. Geneva: WHO, 2015.

[13].  Chen J, Wei X, Li H, Sun K, Zhang Z, Chen P, et al. Study on barriers to anti-TB treatment for rural-to-urban migrant TB patients in Shanghai. Chin J Antituberc 2009; 31:337–340. [Google Scholar].

[14].  Chinese Anti-tuberculosis Association. The Guideline for Drug-resistant Tuberculosis chemotherapy. Chin J Antituberc 2015; 37:421–469. [Google Scholar].

[15].  Marra CA, Marra F, Cox VC. Factors influencing quality of life in patients with active tuberculosis. Health Qual Life Outcomes 2004; 2:58.

[16].  Olusoji D, Elutayo O, Olanrewaju O, Olapade GD. Pre-extensive drug resistant TB among MDR-TB patients. Global Advd Res J Microbiol. 2013; 2:22–5. [Google Scholar].

Lawson L, Yassin MA, Abdurrahman ST, Parry CM, Dacombe R, Sogaolu OM, et al. Resistance to first-line tuberculosis drugs in three cities of Nigeria. Trop Med Int Health. 2011; 16:974–80. [PubMed] [Google Scholar].